CC223 enhances cisplatin sensitivity of platinum-resistant ovarian cancer by inducing cell cycle arrest

Platinum-based chemotherapy is the standard treatment for ovarian cancer. However, the emergence of platinum resistance greatly limits its effectiveness. Investigating novel therapeutic strategies to overcome platinum resistance is imperative to extend survival in ovarian cancer patients. The cytotoxic effects of CC223 on SKOV3DDP and A2780DDP were evaluated using the CCK8 assay. Based on the ovarian cancer organoid model, drug screening testing was employed to assess the sensitivity of ovarian